Current options and future perspectives in the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma.

Ther Adv Hematol · 2022 · PMC9243592 · PMID 35785244

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

In the phase II CAVALLI trial, R-CHOP combined with venetoclax in first-line therapy showed a trend for improved PFS and OS compared with patients with similar characteristics treated on the GOYA study with R-CHOP alone. 95 Mutations of enhancer of zeste homolog 2 ( EZH2 ) are a frequent genetic event in GCB DLBCLs.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.